Balancing Biopharma’s Supply Chain Priorities

Scroll Down

With intense pressure placed upon the biopharmaceutical industry to rapidly develop and produce COVID-19 vaccines, diagnostics and therapeutics, it is imperative that CDMOs adapt to ensure they can deal with the increased demand and existing commitments.

In this roundtable, Bill Vincent, Genezen Founder, provides insight into how COVID-19 has accelerated demand for clinical products and outlines how CDMOs are dealing with this pressure despite constraints on the supply of raw materials as well as manufacturing capacity issues.

Read the full article here.

 

You may also be interested in...

Genezen appoints Chief Commercial Officer to…

  Genezen, a cell and gene therapy Contract Development and Manufacturing...

Read more

Downstream Process Development for Lentiviral Vectors…

Lentiviral vectors (LVV) are commonly used as an efficient and safe...

Read more

Stable cell lines vs transient transfection…

The aim of upstream processing in viral vector development and manufacturing...

Read more

Genezen delivers next phase of cGMP…

Genezen, a cell and gene therapy Contract Development and Manufacturing Organization...

Read more